Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AEM-18
- Development stage
- Preclinical
- Lead developer
- LipimetiX Development
- Modality
- Peptides
- Administration
- Intravenous
01
Overview
**AEM-18** is an apolipoprotein E (APOE) mimetic peptide developed as a potential therapeutic for lipid disorders. It functions as an **APOE agonist**, mimicking the lipid-binding and cholesterol transport functions of native apolipoprotein E to promote reverse cholesterol transport and reduce hypercholesterolemia. Initially developed by **The University of Alabama at Birmingham**, it is part of a series of apoE mimetics (including AEM-28) advanced by **LipimetiX Development**, with demonstrated lipid-lowering effects in preclinical models and potential applications in refractory hypercholesterolemia and related cardiovascular conditions.[5][7]
02
Targets
APOE (Apolipoprotein E)
Beyond the preview
Go deeper on AEM-18.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AEM-18.